Search research articles
Contact Us
Filters
Showing results (161-170 of 276) with videos related to
Page
of 28
Sort By:
Biorxiv : the Preprint Server for Biology
|
May 13, 2026
eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemia
Biljana Culjkovic-Kraljacic, Leandro Marcelo Martinez, Alyssa Retiz, et al.
Blood
|
January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Gail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia
Gail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Blood
|
April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
January 20, 2015
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells
Lina Han, Peng Qiu, Zhihong Zeng, et al.
The Lancet. Oncology
|
October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
Jaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Leukemia
|
March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
Courtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
Haematologica
|
September 11, 2025
Wild-type p53 overexpression in <i>NPM1</i>-mutated acute myeloid leukemia: potential implications for disease biology and therapy response
Paul D Barone, Siarhei Dzedzik, Ashley S Kleinman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
Eric J Feldman, Joseph Brandwein, Richard Stone, et al.
American Journal of Hematology
|
January 19, 2023
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial
Andrew H Wei, Hartmut Döhner, Hamid Sayar, et al.
Page
of 28
Search research articles
Search
Showing results (161-170 of 276) with videos related to
Sort By:
Page
of 28
Biorxiv : the Preprint Server for Biology
|
May 13, 2026
eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemia
Biljana Culjkovic-Kraljacic, Leandro Marcelo Martinez, Alyssa Retiz, et al.
Blood
|
January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Gail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia
Gail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Blood
|
April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
January 20, 2015
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells
Lina Han, Peng Qiu, Zhihong Zeng, et al.
The Lancet. Oncology
|
October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
Jaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Leukemia
|
March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
Courtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
Haematologica
|
September 11, 2025
Wild-type p53 overexpression in <i>NPM1</i>-mutated acute myeloid leukemia: potential implications for disease biology and therapy response
Paul D Barone, Siarhei Dzedzik, Ashley S Kleinman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
Eric J Feldman, Joseph Brandwein, Richard Stone, et al.
American Journal of Hematology
|
January 19, 2023
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial
Andrew H Wei, Hartmut Döhner, Hamid Sayar, et al.
Page
of 28